Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Placebo-controlled, Observer-blinded Phase 1 Study to Assess the Safety and Immunogenicity of Two Different Dose Levels of an Alum Adjuvanted Inactivated Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Flavivirus-naïve Adults Aged 18 to 49 Years

Trial Profile

A Randomized, Placebo-controlled, Observer-blinded Phase 1 Study to Assess the Safety and Immunogenicity of Two Different Dose Levels of an Alum Adjuvanted Inactivated Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Flavivirus-naïve Adults Aged 18 to 49 Years

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Dec 2018

At a glance

  • Drugs VLA-1601 (Primary)
  • Indications Zika virus infection
  • Focus Adverse reactions; First in man
  • Sponsors Valneva
  • Most Recent Events

    • 06 Dec 2018 Status changed from active, no longer recruiting to completed.
    • 19 Nov 2018 According to an Emergent BioSolutions media release, the final analysis at day 208 after first vaccination is expected in the first quarter 2019.
    • 19 Nov 2018 Interim results up to Day 56 were presented in an Emergent BioSolutions media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top